P-188 Safety and efficacy of concurrent carboplatin or cetuximab chemoradiation in cisplatin ineligible locally advanced head and neck squamous cell carcinoma
Joana Marinho(Centro Hospitalar de Vila Nova de Gaia), Diana Moreira(IPO Porto), José Dinis(Instituto Português de Oncologia Francisco Gentil), Cláudia Vieira, André Soares(IPO Porto), Inês Leão(Centro Hospitalar de Vila Nova de Gaia), Ana Joaquim(Centro Hospitalar de Vila Nova de Gaia), André Laranja(IPO Porto)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
|Annals of Oncology|2017|90
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
|Cancer Chemotherapy and Pharmacology|2014|87